ArticleMedicine2025
Exploring the potential mechanisms of OSBPL3 in metabolic dysfunction-associated steatotic liver disease by integrating bulk and single-cell RNA sequencing data.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
OSBPL3 is vital for fatty liver disease, but its immune mechanisms in metabolic dysfunction-associated steatotic liver disease (MASLD) are unclear. This study investigates these mechanisms for MASLD treatment insights. MASLD datasets from public databases were used. OSBPL3 expression was analyzed by t-test in GSE57425, and its function explored via GSEA. Key cell types were identified in GSE129516 by scRNA-seq, followed by cell-to-cell communication and pseudo-temporal analyses. OSBPL3 expression differed significantly between high-fat and normal diet groups (P = .00048). It was enriched in the "oxidative phosphorylation" pathway, hinting at its role in energy metabolism and mitochondrial function in MASLD. Thirteen cell types were identified, with macrophages and monocytes as key types due to expression and cell percentage differences. Macrophages showed closer communication with granulocytes, fibroblasts, and erythrocytes in nonalcoholic steatohepatitis (NASH) diet samples. Macrophage and monocyte differentiation had 9 distinct states, with OSBPL3 highly expressed during metaphase. This study identified macrophages and monocytes as key cell types in OSBPL3's mechanism in MASLD, offering valuable insights for targeted therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.